SNDX Syndax: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

Syndax Pharmaceuticals (SNDX) is diversifying its oncology portfolio through the launch of targeted leukemia therapy programs. The company focuses on developing protein inhibitors, offering revumenib for the treatment of rare mutations. Current operations rely on a significant liquidity reserve to cover R&D expenses. The annual percentage change in earnings per share (TTM) shows a metric value of 34.50, allowing for an assessment of the earnings per share trend.
פילוחי מדדים פיננסיים ומדדי שוק עבור Syndax Pharmaceuticals Inc (SNDX)

This indicator measures the earnings per share (EPS) trend over twelve months, where daily recalculations allow for the real-time capture of market consensus without waiting for quarterly reports. By analyzing the rolling annual EPS change, an investor can assess how the growing scientific authority of Syndax Pharmaceuticals (SNDX) in oncology and the success of clinical trials translate into the actual fundamental value of the business.